Onco360 gains access to latest cancer drug

LOUISVILLE, Ky. — Onco360 on Wednesday announced that it has been selected by Taiho Oncology as a limited distribution pharmacy network participant for Lonsurf (trifluridine and tipiracil). With the addition of Lonsurf, Onco360 continues to grow its broad portfolio of limited distribution oncology medications.

 

“This is yet another example of how our differentiated oncology pharmacy model is gaining traction and recognition in the marketplace," stated Paul Jardina, president and CEO Onco360. "Onco360 is committed to providing patients with the most comprehensive oncology pharmacy care possible, and the addition of Lonsurf provides us with an important new tool in the fight against cancer.”

 

On Sept. 22, 2015, the U.S. Food and Drug Administration approved Lonsurf for patients with an advanced form of colorectal cancer who are no longer responding to other therapies. In 2014, the American Cancer Society estimated that 136,830 people would be diagnosed with metastatic colorectal cancer in the United States. A subset of these patients will become candidates for treatment with Lonsurf.

 

Lonsurf is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.